Latest Biotechnology News

Percheron Therapeutics has announced a $2.2 million non-renounceable entitlement offer at a 20% discount, including free options, to fund the next phase of its lead oncology asset HMBD-002.

Neurizon Therapeutics announces the resignation of CEO Dr Michael Thurn, with Executive Chair Sergio Duchini stepping in temporarily as the company embarks on a global hunt for new leadership.

Tetratherix Limited launches a new precision medicine franchise leveraging its Tetramatrix™ platform, securing a decade-long exclusive partnership with US health group Superpower Health Inc. This deal promises immediate revenue and complements ongoing FDA milestones.

Immutep Limited’s shares have resumed trading following the release of an interim futility analysis from its pivotal TACTI-004 Phase III trial of eftilagimod alfa.

Immutep Limited has discontinued its pivotal TACTI-004 Phase III trial in first-line non-small cell lung cancer following an independent futility analysis, prompting a strategic reassessment of its clinical program and finances.

Imugene Limited has launched a $20 million capital raising through a $12 million institutional placement and an $8 million Share Purchase Plan, alongside a convertible notes amendment to support its clinical development pipeline.

Immutep Limited has voluntarily suspended trading of its shares on the ASX pending the release of a key announcement regarding the interim futility analysis of its TACTI-004 Phase III trial. The suspension underscores the market’s anticipation of potentially pivotal clinical trial results.

Imugene Limited reports striking early results from its Phase 1b azer-cel trial, achieving a 100% overall response rate in chronic lymphocytic leukemia and 80% in marginal zone lymphoma, while broadening its study to include a BTK inhibitor combination.

Clarity Pharmaceuticals has completed enrolment in its Phase III AMPLIFY trial for the Cu-SAR-bisPSMA imaging agent, advancing its bid for FDA approval in prostate cancer diagnostics.

Entropy Neurodynamics has received a $1.73 million R&D tax incentive refund from the Australian Government, reinforcing its clinical development of an intravenous psilocin treatment for neuropsychiatric disorders.

PYC Therapeutics has successfully closed its retail entitlement offer, raising approximately $47 million at $1.50 per new share with a 40% take-up rate. New shares are set to begin trading on the ASX from 9 March 2026.

Chimeric Therapeutics has secured a $1.785 million advance against its anticipated FY26 Research and Development Tax Incentive to bolster its clinical trial pipeline and working capital.